Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Pharming gets venture funds
February 13, 2006
| A version of this story appeared in
Volume 84, Issue 7
Dutch biotech company Pharming has entered a $30 million agreement with Paul Royalty Fund concerning recombinant human C1 inhibitor for the treatment of hereditary angioedema. Pharming has received up-front payments of $20 million, of which $3.5 million is an equity investment by Paul Royalty. Pharming is also eligible to receive up to $10 million in milestone payments based on approval and launch of the inhibitor in the U.S. Paul Royalty is entitled to receive single-digit royalties on sales of the inhibitor and on other Pharming products over the agreement's 10-year term.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X